Trial Outcomes & Findings for Clinical Validation of AI-Based System for Continuous Remote Monitoring of Patient Severity - Experts' Opinion (NCT NCT06237036)

NCT ID: NCT06237036

Last Updated: 2026-03-19

Results Overview

The Clinical Utility Questionnaire (CUS) is a 13-item instrument assessing the practical value of the Legit.Health Plus device. Scale Ranges: Items 1-10 use a 0-10 Likert scale (0=lowest utility, 10=highest). Items 11-12 are binary, scored as 0 (No) or 10 (Yes). Item 13 is categorical, scored as 0, 4, 8, or 10 based on the amount of consultation time saved. Calculation Method: The Total Raw Score is the sum of all 13 items (Minimum: 0; Maximum: 130). This raw sum is normalized to a 10-point scale using the formula: (Total Raw Score / 130) × 10. Interpretation: The final result is reported as a score from 0 to 10. Higher scores indicate greater perceived clinical utility. A score of 8.0 or higher was the pre-specified threshold for successful validation of the device's utility.

Recruitment status

COMPLETED

Target enrollment

160 participants

Primary outcome timeframe

At the conclusion of the study evaluation period, up to 18 months.

Results posted on

2026-03-19

Participant Flow

Recruitment occurred at the Hospital Universitario de Torrejón's Dermatology Department. Investigators identified eligible participants in a community healthcare setting. The recruitment period spanned 18 months, from April 13, 2022, to October 23, 2023. Researchers used the Patient Information Sheet to explain study details before obtaining informed consent. A total of 160 participants were enrolled.

Following enrollment, a significant screening process was conducted to ensure protocol adherence. Of the 400 potential participants initially considered, 240 individuals were excluded primarily due to low protocol adherence. This meticulous selection process ensured that only the 160 participants meeting all predefined eligibility criteria proceeded to the data collection phase. No additional washout or run-in periods were required.

Participant milestones

Participant milestones
Measure
Patients With the Specified Chronic Dermatological Conditions
The study encompasses patients diagnosed with any of the specified chronic dermatological conditions that meet the inclusion criteria. These patients are attended at the Dermatology Department of the Hospital Universitario de Torrejón. Treatment Patients participating in this study did not receive any specific treatment as part of the research protocol. Concomitant Medication/Treatment Patients continued their regular prescribed medications and treatments as directed by their primary healthcare providers. No additional medications or treatments were administered as part of this study. Follow-Up Duration The follow-up period extended for seven months. Throughout this duration, patients underwent a minimum of two follow-up visits, which could be conducted either remotely or in-person, as per the study\'s protocol.
Overall Study
STARTED
160
Overall Study
COMPLETED
160
Overall Study
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Clinical Validation of AI-Based System for Continuous Remote Monitoring of Patient Severity - Experts' Opinion

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Patients With the Specified Chronic Dermatological Conditions
n=160 Participants
The study encompasses patients diagnosed with any of the specified chronic dermatological conditions that meet the inclusion criteria. These patients are attended at the Dermatology Department of the Hospital Universitario de Torrejón. Treatment Patients participating in this study did not receive any specific treatment as part of the research protocol. Concomitant Medication/Treatment Patients continued their regular prescribed medications and treatments as directed by their primary healthcare providers. No additional medications or treatments were administered as part of this study. Follow-Up Duration The follow-up period extended for seven months. Throughout this duration, patients underwent a minimum of two follow-up visits, which could be conducted either remotely or in-person, as per the study\'s protocol.
Age, Continuous
64 Years
STANDARD_DEVIATION 19 • n=110 Participants
Sex: Female, Male
Female
92 Participants
n=110 Participants
Sex: Female, Male
Male
68 Participants
n=110 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=110 Participants
Race (NIH/OMB)
Asian
0 Participants
n=110 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
3 Participants
n=110 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=110 Participants
Race (NIH/OMB)
White
157 Participants
n=110 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=110 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=110 Participants

PRIMARY outcome

Timeframe: At the conclusion of the study evaluation period, up to 18 months.

The Clinical Utility Questionnaire (CUS) is a 13-item instrument assessing the practical value of the Legit.Health Plus device. Scale Ranges: Items 1-10 use a 0-10 Likert scale (0=lowest utility, 10=highest). Items 11-12 are binary, scored as 0 (No) or 10 (Yes). Item 13 is categorical, scored as 0, 4, 8, or 10 based on the amount of consultation time saved. Calculation Method: The Total Raw Score is the sum of all 13 items (Minimum: 0; Maximum: 130). This raw sum is normalized to a 10-point scale using the formula: (Total Raw Score / 130) × 10. Interpretation: The final result is reported as a score from 0 to 10. Higher scores indicate greater perceived clinical utility. A score of 8.0 or higher was the pre-specified threshold for successful validation of the device's utility.

Outcome measures

Outcome measures
Measure
Dermatologists Assessing the Device
n=6 Participants
The dermatologist group consisted of six experienced specialists from the Dermatology Department of the Hospital Universitario de Torrejón. These practitioners acted as both investigators and primary users of the Legit Health Plus device (Version 1.1.0.0). As members of this study group, the dermatologists experienced the following: Clinical Evaluation and Monitoring: Specialists used the AI-powered device to remotely track the progression and severity of chronic skin conditions in 160 participants over an 18-month period. Time Optimization: Practitioners utilized the tool to streamline their workflow, aiming to optimize consultation times and prioritize patients based on automated severity assessments. Data Management: They had secure, credentialed access to a web-based platform to review high-quality clinical photographs and symptoms reported by participants from their homes. Standardized Assessment: Specialists were tasked with completing several standardized evaluations to judge the device, including the Clinical Utility Questionnaire (CUS), the System Usability Scale (SUS), and the Data Utility Questionnaire (DUQ). Regulatory Compliance: The group adhered to Good Clinical Practice (GCP) and international standards (ISO 14155:2021) while maintaining a separate, secure list to connect participant codes with clinical data. This group was purposefully kept small to minimize inter-observer variability and ensure consistent, high-quality data collection
Clinical Utility Questionnaire (CUS) Score
7.39 Units on a scale
Standard Deviation 2.25

SECONDARY outcome

Timeframe: Assessed once at the conclusion of the participant's evaluation phase, at the final study visit (up to 18 months).

The System Usability Scale (SUS) is a standardized 10-item survey used to evaluate the usability and learnability of the Legit.Health Plus medical device. Scale Ranges: Each item is rated on a 5-point Likert scale from 1 (Strongly Disagree) to 5 (Strongly Agree). Calculation Method: To calculate the SUS score, individual item responses are transformed into a 0-4 scale. For odd-numbered items (1, 3, 5, 7, 9), the score is the scale position minus 1. For even-numbered items (2, 4, 6, 8, 10), the score is 5 minus the scale position. The sum of these ten transformed scores is then multiplied by 2.5 to normalize the total result to a 10-point scale. Formula: (Sum of Transformed Item Scores) × 2.5. Interpretation: The final score ranges from 0 to 10. Higher scores indicate better usability. A score of 6.8 or higher is generally considered above average clinical usability.

Outcome measures

Outcome measures
Measure
Dermatologists Assessing the Device
n=6 Participants
The dermatologist group consisted of six experienced specialists from the Dermatology Department of the Hospital Universitario de Torrejón. These practitioners acted as both investigators and primary users of the Legit Health Plus device (Version 1.1.0.0). As members of this study group, the dermatologists experienced the following: Clinical Evaluation and Monitoring: Specialists used the AI-powered device to remotely track the progression and severity of chronic skin conditions in 160 participants over an 18-month period. Time Optimization: Practitioners utilized the tool to streamline their workflow, aiming to optimize consultation times and prioritize patients based on automated severity assessments. Data Management: They had secure, credentialed access to a web-based platform to review high-quality clinical photographs and symptoms reported by participants from their homes. Standardized Assessment: Specialists were tasked with completing several standardized evaluations to judge the device, including the Clinical Utility Questionnaire (CUS), the System Usability Scale (SUS), and the Data Utility Questionnaire (DUQ). Regulatory Compliance: The group adhered to Good Clinical Practice (GCP) and international standards (ISO 14155:2021) while maintaining a separate, secure list to connect participant codes with clinical data. This group was purposefully kept small to minimize inter-observer variability and ensure consistent, high-quality data collection
System Usability Scale (SUS) Score
8.70 Units on a scale
Standard Deviation 1.58

SECONDARY outcome

Timeframe: Assessed once at the conclusion of the participant's evaluation phase, at the final study visit (up to 18 months).

This 8-item questionnaire assesses user experience and satisfaction with the Legit.Health Plus device for remote monitoring. Scale Ranges: Each of the 8 items (e.g., ease of use, empowerment, and support) is rated on a Likert scale from 0 to 10. For most items, 0 represents the lowest level of satisfaction (e.g., "Very difficult" or "Strongly disagree") and 10 represents the highest (e.g., "Very easy" or "Strongly agree"). Calculation Method: The total score is the arithmetic mean of the responses to the 8 individual items. The sum of all item scores is divided by 8 to produce a single value. Interpretation: The final score ranges from 0 to 10. Higher scores indicate greater patient satisfaction with the remote monitoring system and the care received through the application.

Outcome measures

Outcome measures
Measure
Dermatologists Assessing the Device
n=160 Participants
The dermatologist group consisted of six experienced specialists from the Dermatology Department of the Hospital Universitario de Torrejón. These practitioners acted as both investigators and primary users of the Legit Health Plus device (Version 1.1.0.0). As members of this study group, the dermatologists experienced the following: Clinical Evaluation and Monitoring: Specialists used the AI-powered device to remotely track the progression and severity of chronic skin conditions in 160 participants over an 18-month period. Time Optimization: Practitioners utilized the tool to streamline their workflow, aiming to optimize consultation times and prioritize patients based on automated severity assessments. Data Management: They had secure, credentialed access to a web-based platform to review high-quality clinical photographs and symptoms reported by participants from their homes. Standardized Assessment: Specialists were tasked with completing several standardized evaluations to judge the device, including the Clinical Utility Questionnaire (CUS), the System Usability Scale (SUS), and the Data Utility Questionnaire (DUQ). Regulatory Compliance: The group adhered to Good Clinical Practice (GCP) and international standards (ISO 14155:2021) while maintaining a separate, secure list to connect participant codes with clinical data. This group was purposefully kept small to minimize inter-observer variability and ensure consistent, high-quality data collection
Patient Satisfaction Questionnaire Score
7.07 Units on a scale
Standard Deviation 2.83

SECONDARY outcome

Timeframe: Collected once at the end of the 6-month follow-up period for each participant.

The Data Utility Questionnaire (DUQ) is a standardized 5-item survey used to evaluate the utility of the information provided by the Legit.Health Plus medical device in the clinical consultation. Scale Ranges: Each item is rated on a 5-point Likert scale from 1 (Strongly Disagree) to 5 (Strongly Agree). Calculation Method: To calculate the DUQ score, individual item responses are transformed into a 0-4 scale. The sum of these five scores is then multiplied by 100 and divided by (5\*5) to normalize the total result to a 10-point scale. Formula: (Sum of Transformed Item Scores) × 100/(5\*5). Interpretation: The final score ranges from 0 to 100. Higher scores indicate better usability. A score of 6.8 or higher is generally considered above average clinical usability.

Outcome measures

Outcome measures
Measure
Dermatologists Assessing the Device
n=6 Participants
The dermatologist group consisted of six experienced specialists from the Dermatology Department of the Hospital Universitario de Torrejón. These practitioners acted as both investigators and primary users of the Legit Health Plus device (Version 1.1.0.0). As members of this study group, the dermatologists experienced the following: Clinical Evaluation and Monitoring: Specialists used the AI-powered device to remotely track the progression and severity of chronic skin conditions in 160 participants over an 18-month period. Time Optimization: Practitioners utilized the tool to streamline their workflow, aiming to optimize consultation times and prioritize patients based on automated severity assessments. Data Management: They had secure, credentialed access to a web-based platform to review high-quality clinical photographs and symptoms reported by participants from their homes. Standardized Assessment: Specialists were tasked with completing several standardized evaluations to judge the device, including the Clinical Utility Questionnaire (CUS), the System Usability Scale (SUS), and the Data Utility Questionnaire (DUQ). Regulatory Compliance: The group adhered to Good Clinical Practice (GCP) and international standards (ISO 14155:2021) while maintaining a separate, secure list to connect participant codes with clinical data. This group was purposefully kept small to minimize inter-observer variability and ensure consistent, high-quality data collection
Utility Questionnaire (DUQ) Score
87.3 Units on a scale
Standard Deviation 16.1

Adverse Events

Patients With the Specified Chronic Dermatological Conditions

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Jordi Barrachina - Clinical Affairs Manager

AI Labs Group S.L.

Phone: +34 653 08 83 37

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place